Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Transitional Cell 29 Carcinoma, Non-Small-Cell Lung 29 Urinary Bladder Neoplasms 26 Neoplasms 22 Carcinoma, Renal Cell 22 Carcinoma, Merkel Cell 21 Neoplasm Metastasis 18 Colorectal Neoplasms 16 Breast Neoplasms 16 Squamous Cell Carcinoma of Head and Neck 15 Ovarian Neoplasms 14 Triple Negative Breast Neoplasms 11 Pancreatic Neoplasms 9 Melanoma 9 Head and Neck Neoplasms 8 Stomach Neoplasms 7 Recurrence 6 Carcinoma, Hepatocellular 6 Ureteral Neoplasms 5 Small Cell Lung Carcinoma 5 Prostatic Neoplasms 5 Urethral Neoplasms 4 Sarcoma 4 Neuroendocrine Tumors 4 Leukemia, Myeloid, Acute 4 Glioblastoma 4 Carcinoma, Squamous Cell 4 Uterine Cervical Neoplasms 3 Turcot syndrome 3 Skin Neoplasms 3

Interventions

Gemcitabine 4 130-nm albumin-bound paclitaxel 2 sintilimab 1 nimotuzumab 1 avelumab 1 Taxes 1 Oxaliplatin 1 Leucovorin 1 Irinotecan 1 Hydroxychloroquine 1 Fluorouracil 1 Capecitabine 1 Antineoplastic Agents 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Cancer Resectable × avelumab × Clear all

NCT03344172 2020-05-14

17-134

University of Pittsburgh

Phase 2 Terminated

32 enrolled 14 charts

Gastrointestinal

Pancreatic Cancer Resectable

Data powered by HemOnc (CC BY 4.0) Colophon ⚡